US20020115682A1 - Agents for treating neurodegenerative disorders - Google Patents

Agents for treating neurodegenerative disorders Download PDF

Info

Publication number
US20020115682A1
US20020115682A1 US10/057,688 US5768802A US2002115682A1 US 20020115682 A1 US20020115682 A1 US 20020115682A1 US 5768802 A US5768802 A US 5768802A US 2002115682 A1 US2002115682 A1 US 2002115682A1
Authority
US
United States
Prior art keywords
treatment
weeks
patients
pyrido
dimebon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/057,688
Inventor
Nikolai Zefirov
Andrei Afanasiev
Svetlana Afanasieva
Sergei Bachurin
Sergei Tkachenko
Vladimir Grigoriev
Marina Jurovskaya
Valery Chetverikov
Elizaveta Bukatina
Irina Grigorieva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivation Neurology Inc
Original Assignee
AFANAS'EV A Z
AFANAS'EVA S V
BUKATINA E E
CHETVERIKOV V P
GRIGOR'EV V V
GRIGOR'EVA I V
TKACHENKO S E
YUROVSKAYA M A
ZEFIROV N S
Selena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AFANAS'EV A Z, AFANAS'EVA S V, BUKATINA E E, CHETVERIKOV V P, GRIGOR'EV V V, GRIGOR'EVA I V, TKACHENKO S E, YUROVSKAYA M A, ZEFIROV N S, Selena Pharmaceuticals Inc filed Critical AFANAS'EV A Z
Priority to US10/057,688 priority Critical patent/US20020115682A1/en
Assigned to SELENA PHARMACEUTICALS, INC. reassignment SELENA PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BACHURIN, SERGEI O., AFANASIEV, ANDREI Z., AFANASIEVA, SVETLANA V., BUKATINA, ELIZAVETA E., CHETVERIKOV, VALERY P., GRIGORIEV, VLADIMIR V., GRIGORIEVA, IRINA V., JUROVSKAYA, MARINA A., TKACHENKO, SERGEI E., ZEFIROV, NIKOLAI S.
Publication of US20020115682A1 publication Critical patent/US20020115682A1/en
Priority to US10/652,435 priority patent/US20040044022A1/en
Assigned to MEDIVATION, INC. reassignment MEDIVATION, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SELENA PHARMACEUTICALS, INC.
Priority to US11/004,001 priority patent/US7071206B2/en
Priority to US11/361,628 priority patent/US20060140866A1/en
Assigned to MEDIVATION NEUROLOGY, INC. reassignment MEDIVATION NEUROLOGY, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEDIVATION, INC.
Assigned to GRIGOR'EVA, I. V., YUROVSKAYA, M. A., AFANAS'EV, A. Z., GRIGOR'EV, V. V., ZEFIROV, N. S., CHETVERIKOV, V. P., BACHURIN, S. O., BUKATINA, E. E., TKACHENKO, S. E., AFANAS'EVA, S. V. reassignment GRIGOR'EVA, I. V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: INSTITUTE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES OF THE RUSSIAN ACADEMY OF SCIENCES
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to the use of chemical compounds in medicine, more specifically, to the use of the compounds selected from hydrogenated pyrido[4,3-b]indoles for the treatment of neurodegenerative diseases, and especially Alzheimer's disease (AD), due to the discovery of new properties intrinsic to these compounds.
  • AD Alzheimer's disease
  • tacrine hydrochloride which is 9-amino-1,2,3,4-tetrahydroacridine hydrochloride represented by the formula (A):
  • the mechanism of action of the said agent involves inhibiting choline esterase (Volger B. W. “Alternatives in the treatment of memory loss in patient with Alzheimer's disease. (Clinical Pharmacy. Jun. 10, 1991 (6): 447-56).
  • tacrine is an analogue of the world famous physostigmine and is a traditional anticholine esterase agent.
  • the treatment with tacrine is not always effective. Besides, tacrine tends to cause undesirable side-effects.
  • a wide range of neurological diseases such as Alzheimer's disease, Huntington chorea, amiotrophic lateral sclerosis as well as brain ischemia are known to be associated with an excitotoxic effect of neuromediatory excitatory amino acids (EAA) such as glutamate and aspartate (Excitatory Amino Acids and Drug Research, Ed. by M. R. Szewczak N. I. Hrib Alan R. Liss, Inc., New York, 1989, p.380; The NMDA Receptor. Eds. Watkins & Collingridge G., 1989, IRL Press). In accordance with this mechanism.
  • EAA neuromediatory excitatory amino acids
  • NMDA N-methyl-D-aspartate
  • ⁇ -amyloid is a neurotoxic factor inducing neurodegenerative processes in the neurones.
  • ⁇ -Amyloid is present in the neurotic plaques abundantly located on the surface of the brain of the patients suffering from Alzheimer's disease (Prelli et al.,—J. Neurochem., 1988, v.51, p.648; Yanuer et al.,—Science, 1990, v.250. p.279). As shown by the investigations of recent years.
  • ⁇ -amyloid significantly enhances the excitotoxic effect of glutamate which is effected through the NMDA-receptor system (Koh et al., Brain Res., 1990, v.533, p.315; Mattson et al.,—J. Neurosci., 1992, v. 12, p.376).
  • glutamate mediator at concentrations that are nontoxic under normal conditions becomes toxic for neurones under conditions of the developing ⁇ -amyloid dose and causes their death.
  • NMDA receptor antagonist- is 2-amino-5-phosphonovaleric acid (AP5)
  • AP5 2-amino-5-phosphonovaleric acid
  • ED 50 190 mg/kg
  • An intensive search for and trials of the agents having the anti-NMDA properties but without the neurotoxic effects is currently under way for treatment of the neurodegenerative diseases. However, to date such agents have not been available in clinics.
  • the present invention provides compounds and methods of using these compounds to treat neurodegenerative diseases, especially Alzheimer's disease.
  • the compounds that are provided for the treatment of neurodegenerative diseases can be represented by a general formula (I):
  • R 1 is Me, Et or PhCH 2 ;
  • R 2 is H. PhCH 2 or 6-Me-3-Py-(CH 2 ); and
  • R 3 is H, Me or Br.
  • the object of the invention is to provide compounds having a high anti-NMDA activity and producing no side- and toxic effects.
  • hevotroline (8-fluoro-2)(3-(3-pyridyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole dihydrochloride) is an antipsychotic and anxiolytic agent (Abou-Gharbi M., Patel U. R., Webb, M. B., Moyer J. A., Ardnee T. H., J. Med. Chem.. 1987, vol.30, p.1818-1823).
  • the compounds that are provided for the treatment of neurodegenerative diseases can be represented by a general formula (I):
  • R 1 is Me, Et or PhCH 2
  • R 2 is H, PhCH 2 or 6-Me-3-Py-(CH 2 ) 2
  • R 3 is H, Me or Br.
  • the animals inoculated with a saline solution were used as control.
  • the injection of NMDA into the lateral ventricle in a dose of 0.1 ⁇ g per mouse caused run, jumps, convulsions and then the death of the animals.
  • the preinjection of the test substances prevented the development of convulsions and death of the animals.
  • the ED 50 value (the dose of the agent preventing the development of convulsions and the death of 50% of the animals) was determined by a probit-analysis method (Litchfild J. T., Wicoxon F. J.-Pharmacol. Exp.Therap., 1949, v. 96, p. 99-114).
  • the “dimebon” agent (compound No. 10, Table A) which is used in medicine as an antiallergic agent (Inventor's Certificate No. 1138164, IP Class A61K 31/47,5. C07 D 209/52, published on Feb. 7, 1985) was also clinically tested as an agent for treatment of Alzheimer's disease.
  • the carbidine agent (compound No. 4) is less suitable for preliminary clinical tests due to its obvious psychotropic effect capable of masking some manifestations of positive treatment results. Dimebon is non-toxic and does not show any negative side-effects.
  • the test was carried out under the direct supervision bv two of the inventors. namely E. E. Bukatina and V. Grigorieva, in 14 patients who agreed to take part in the tests, 13 of whom lived in a boarding house for senile persons and one patient lived with her family.
  • Alzheimer's disease was diagnosed on the basis of criteria ICD-10 NINCDS ADRDA.
  • CT computer tomography
  • Dimebon in the form of tablets (comprising 10 mg of dimebon, 30 mg of lactose, 5 mg of magnesium stearate was prescribed for oral administration in a dose of 0.02 g three times a day.
  • the patients living in the boarding house received dimebon for 58 days.
  • the 0 score indicates the poorest result; on the contrary, according to the inventors'scale, the 0 score indicates the absence of a symptom 4 score indicates the greatest manifestation thereof.
  • the degree of disturbance of some function proved to be between the two evaluation indices, the value was of intermediate type. e.g. 0.5, 1.5, or the like.
  • the patients had been independently examined bv two doctors who used the inventors' scale. The examination during the treatment was carried out by the doctors using both the scales.
  • the evaluation according to all the inventors' scale points during all the tests and their variations during the treatment with dimebon are given in the Appendix.
  • the degree of the disturbance if the cognitive functions was determined by a sum of evaluations according to the first 5 scale points reflecting the condition of memory, orientation and relation with the reality.
  • the disturbance of speech was dealt with separately and was determined by a sum of evaluations according to items 6b-6d. No disturbances of articulation (item 6a) corresponding to peculiar disturbances of speech functions in Alzheimer's disease were observed in any cases.
  • test results reflected the condition of the patients at the time of the examination. Any changes in the metal state observed in the interval between the tests and disappearing by the moment of examination according to the scale were described in the section “Clinical Observations”.
  • Table 3 The test results of 7 patients with relatively mild dementia are presented in Table 3. This group included the patients whose evaluation for each of the inventor's 5-point scale did not exceed 2.5 scores. In fact. only one of the patients had such score (observation 2) according to the 3rd scale point (memory for the past). All the other patients had lower scores. As can be seen from Table 2. against the background of treatment with dimebon there is a trend for improvement which becomes more marked with an increase in the duration of the therapy.
  • Psychopathic-like symptoms (lack of restraint, touchiness, conflict making, evil-mindedness or aggressiveness) in all 7 patients who suffered from them decreased significantly during the first 2 weeks or therapy. A distinct antidepressive effect of the agent was also observed in 8 patients. One of them (observation 10) showed no lower spirits during the test period, but, as the medical stuff reported, she had frequent disphorias which ceased during dimebon administration. Besides, the patient herself (dementia was not profound in this case) constantly emphasized that her mood improved during the treatment.
  • a pilot research of the effectiveness of dimebon in 14 patients suffering from Alzheimer's disease revealed definite positive effect of the agent on psychopatic-like and depressive manifestations.
  • the examinations carried out using Hazegawa's scale and the inventor's scale revealed a significant improvement in cognitive functions especially in patients with mild dementia.
  • Headache 1 1 0 0.5 — 0 — 2 1 1 0 +1 1 — 3 0 0 0 — 0 — 4 2 2 1 +1 2 — 5 2.5 2 0 +2 1.5 +0.5 6 0 0.5 0 — 0.5 — 7 2 3 0 +2 0 +2 8 0 0 0 — 0 — 9 0 0 0 — 0 — 10 3 1.5 0 +1.5 0 +1.5 11 3 2 3 — 3 — 12 2 0 0 — 0 — 13 0 0 0 — 0 — 14 0 0 0 — 1 ⁇ 1 17.
  • Spontaneous activity 1 1 2.5 1.5 — 1 — 2 2 1 1 — 1.5 — 3 0.5 0.5 0.5 — 0 — 4 2 2 2 — 1 +1 5 1 1 1 — 1 — 6 1 2 1 — 1 0 7 2 1 1 — 1 — 8 1.5 0 1 — 1 — 9 2 2 2 — 2 0 10 0 0 0 — 0 — 11 2 2 2 — 2 — 12 3 3 3 — 4 ⁇ 1 13 2 1 2 — 1 0 14 0 0 0 — 0 — 20.
  • Item 11 Visual hallucinations were observed for some days in one female patient (obsrvation 9) on the 4th week of therapy.

Abstract

Compounds and methods of using these compounds to treat neurodegenerative diseases, especially Alzheimer's disease, are provided. The compounds that are provided for the treatment of neurodegenerative diseases can be represented by a general formula (I):
Figure US20020115682A1-20020822-C00001
wherein R1 is Me, Et or PhCH2; R2 is H, PHCH2 or 6-Me-3-Py-(CH2)2; and R3 is H, Me or Br. The solid line accompanied by the dotted line, i.e.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0001]
  • The present invention relates to the use of chemical compounds in medicine, more specifically, to the use of the compounds selected from hydrogenated pyrido[4,3-b]indoles for the treatment of neurodegenerative diseases, and especially Alzheimer's disease (AD), due to the discovery of new properties intrinsic to these compounds. [0002]
  • 2. Description of the Related Art [0003]
  • Alzheimer's disease is currently one of the severest and widely spread neurodegenerative diseases. The most traditional approach to the treatment of this disease is compensatory therapy based on the compensation of the cholinergic system functions which are reduced in Alzheimer's disease. One of the therapeutic agents used in the alleged method of treatment is tacrine hydrochloride (hereinafter referred to as tacrine) which is 9-amino-1,2,3,4-tetrahydroacridine hydrochloride represented by the formula (A): [0004]
    Figure US20020115682A1-20020822-C00002
  • The mechanism of action of the said agent involves inhibiting choline esterase (Volger B. W. “Alternatives in the treatment of memory loss in patient with Alzheimer's disease. (Clinical Pharmacy. Jun. 10, 1991 (6): 447-56). As for the choline esterase inhibiting activity, tacrine is an analogue of the world famous physostigmine and is a traditional anticholine esterase agent. However, the treatment with tacrine is not always effective. Besides, tacrine tends to cause undesirable side-effects. [0005]
  • A wide range of neurological diseases such as Alzheimer's disease, Huntington chorea, amiotrophic lateral sclerosis as well as brain ischemia are known to be associated with an excitotoxic effect of neuromediatory excitatory amino acids (EAA) such as glutamate and aspartate (Excitatory Amino Acids and Drug Research, Ed. by M. R. Szewczak N. I. Hrib Alan R. Liss, Inc., New York, 1989, p.380; The NMDA Receptor. Eds. Watkins & Collingridge G., 1989, IRL Press). In accordance with this mechanism. hyperexcitation of neurones in prolonged activation of their N-methyl-D-aspartate (NMDA) receptors with glutamate results in an excessive entry of potassium ions into the cell which initiates a number of pathological metabolic processes finally causing the death of nerve cells (Mattson. Neurone, 1990, v.2, p.105, Mill S. Kater, Neuron, 1990, v.2. p.149; Saitch et al. Lab Suvest. 1991, v.64, p.596). [0006]
  • More specifically in Alzheimer's disease, death of numerous neurones is believed to occur as follows. An endogenic oligopeptide, such as β-amyloid, is a neurotoxic factor inducing neurodegenerative processes in the neurones. β-Amyloid is present in the neurotic plaques abundantly located on the surface of the brain of the patients suffering from Alzheimer's disease (Prelli et al.,—J. Neurochem., 1988, v.51, p.648; Yanuer et al.,—Science, 1990, v.250. p.279). As shown by the investigations of recent years. β-amyloid significantly enhances the excitotoxic effect of glutamate which is effected through the NMDA-receptor system (Koh et al., Brain Res., 1990, v.533, p.315; Mattson et al.,—J. Neurosci., 1992, v. 12, p.376). As a result. the glutamate mediator at concentrations that are nontoxic under normal conditions becomes toxic for neurones under conditions of the developing β-amyloid dose and causes their death. [0007]
  • In this connection. the search for effective antagonists of the brain NMDA-receptors capable of preventing the realization of the neurotoxic effect of EAA appears to be an original and promising approach to creation of neuroprotectors of a wide spectrum of activity including agents which can prevent the development of Alzheimer's disease and be useful for treatment of such diseases as Alzheimer's disease (Maragos W. F. et al., Trends Neurosci.,1987, No. 10, p.65). [0008]
  • A well known NMDA receptor antagonist-is 2-amino-5-phosphonovaleric acid (AP5) (Evans et al.,—Brit. J. Pharmacol., 1982, v.75, p.65). The main disadvantage of AP5 compound a side neurotoxic effect (such as the disturbance of coordination of movement and a sedative effect) which becomes apparent when AP5 is used in the doses in which it produces anti-NMDA effect (ED[0009] 50=190 mg/kg) (Grigoriev et al. Chim. Pharm. Journal, 1988, No.3, p. 275-277). An intensive search for and trials of the agents having the anti-NMDA properties but without the neurotoxic effects is currently under way for treatment of the neurodegenerative diseases. However, to date such agents have not been available in clinics.
    • SUMMARY OF THE INVENTION
  • The present invention provides compounds and methods of using these compounds to treat neurodegenerative diseases, especially Alzheimer's disease. [0010]
  • According to the present invention, the compounds that are provided for the treatment of neurodegenerative diseases can be represented by a general formula (I): [0011]
    Figure US20020115682A1-20020822-C00003
  • wherein R[0012] 1 is Me, Et or PhCH2; R2 is H. PhCH2 or 6-Me-3-Py-(CH2); and R3 is H, Me or Br. The solid line accompanied by the dotted line, i.e.
    Figure US20020115682A1-20020822-P00900
    represents a single or double bond and salts thereof with pharnacologically acceptable acids.
  • When [0013]
    Figure US20020115682A1-20020822-P00900
    represents a single bond. then R1=R3=Me; R2=H; and the compound is in the form of a cis (±) isomer. When
    Figure US20020115682A1-20020822-P00900
    represents a double bond, then
  • (i) R[0014] 1=Et or PhCH2, R2=R3=H,
  • (ii) R[0015] 1=R3=Me, R2=PhCH2,
  • (iii) R[0016] 1=Me, R2=6-Me-3-Py-(CH2)2, R3=H,
  • (iv) R[0017] 1=R3=Me, R2=6-Me-3-Py-(CH2)2,
  • (v) R[0018] 1=Me, R2=H,R3=H or Me,
  • (vi) R[0019] 1=Me, R2=H. R3=Br, and salts thereof with pharmacologically acceptable acids and quatemized derivatives.
  • Particular examples of the compound described above are: [0020]
  • 1. 2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; [0021]
  • 2. 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole and its methyliodide; [0022]
  • 3. cis(±) 2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole and its dihydrochloride; [0023]
  • 4. 2-methyl-8-bromo-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole and its hydrochloride; [0024]
  • 5. 2-ethyl-2.3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; [0025]
  • 6. 2-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; [0026]
  • 7. 2,8-dimethyl-5-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole and its hydrochloride; [0027]
  • 8. 2-methyl-5-[2-(6-methyl-3-pyridyl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole and its sesquisulfate monohydrate: [0028]
  • 9. 2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole and its dihydrochloride. [0029]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The object of the invention is to provide compounds having a high anti-NMDA activity and producing no side- and toxic effects. [0030]
  • As one of the approaches is to search for such agents in the known chemical compounds, from which the inventors have tried to reveal new unexpected (in this case. anti-NMDA) properties which are not due to the chemical structure of the compounds. [0031]
  • The inventors have carried out large-scale investigations of some known compounds which are tetra- and hexahydro-1H-pyrido[4,3-b]indole derivatives that manifest a broad spectrum of biological activity. In the series of 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles the following types of activity were found: antihistamine activity (OS-DE NN 1.813 229, Dec. 6, 1968; 1.952.80, Oct. 20, 1969), central depressive and antiinflammatory activity (U.S. Pat. No.3,718,657 Dec. 13, 1970), neuroleptic activity (Herbert C. A., Plattner S. S., Wehch W. N.-Mol.Pharm. 1980, v.17, N 1, p.38-42) and others. 2.3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole derivatives show psychotropic (Welch W. H., Herbert C. A., Weissman A., Koe K. B. J.Med.Chem.,1986. vol.29, No. 10. p.2093-2099), antiaggressive, antiarrhythmic and other types of activity. [0032]
  • Several drugs such as diazoline (mebhydroline), dimebon, dorastine, carbidine(dicarbine), stobadine, hevotroline based on tetra- and hexahydro-1H-pyrido[4,3-b]indole derivatives are being manufactured. Diazoline(2-methyl-5-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole dihydrochloride) (Klyuev M. A., Drugs, used in “Medical Pract.”, USSR, Moscow, “Meditzina” Publishers, 1991, p.512) and dimebon (2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)ethyl-2,3,4,5- tetrahydro-1H-pyrido[4,3-b]indole dihydrochloride) (M. D. Mashkovskv. “Medicinal Drugs” in 2 vol. Vol. 1-12th Edition. Moscow. “Meditzina” Publishers, 1993, p.383) as well as its closest analogue dorastine(2-methyl-8-chloro-5-[2-(6-methyl-3-pyridyl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole dihydrochloride) (USAN and USP dictionary of drugs names (United States Adopted Names, 1961-1988, current US Pharmacopeia and National Formular for Drugs and other nonproprietary drug names), 1989, 26th Edition., p.196) are known as antihistamine drugs; carbidine (dicarbine) (cis(±)-2.8S-dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole dihydrochloride) is a national neuroleptic agent having an antidepressive effect (L. N. Yakhontov. R. G. Glushkov. Synthetic Drugs, ed. bv A. G. Natradze. Moscow. “Meditzina” Publishers. 1983. p.234-237), and its (-)isomer. stobadine. is known as an antiarrythmic agent (Kitlova M., Gibela P., Drimal J., Bratisl. Lek.Listy, 1985. vol.84, No.5, p.542-549); hevotroline (8-fluoro-2)(3-(3-pyridyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole dihydrochloride) is an antipsychotic and anxiolytic agent (Abou-Gharbi M., Patel U. R., Webb, M. B., Moyer J. A., Ardnee T. H., J. Med. Chem.. 1987, vol.30, p.1818-1823). [0033]
  • However no NMDA receptor antagonists have been found so far among tetra- and hexahydro-1H-pyrido[4,3-b]indole derivatives. [0034]
  • The inventors have quite unexpectedly found that hydrogenated pyrido[4,3-b]indole derivatives are endowed with such properties. It has been found in particular. that a number of known hydrogenated pyrido[3,4-b]indole derivatives have NMDA antagonist properties, which makes them useful for treating neurodegenerative diseases, especially Alzheimer's disease. [0035]
  • According to the present invention, the compounds that are provided for the treatment of neurodegenerative diseases can be represented by a general formula (I): [0036]
    Figure US20020115682A1-20020822-C00004
  • wherein R[0037] 1 is Me, Et or PhCH2,; R2 is H, PhCH2 or 6-Me-3-Py-(CH2)2; and R3 is H, Me or Br. The solid line accompanied by the dotted line, i.e.
    Figure US20020115682A1-20020822-P00900
    represents a single or double bond and salts thereof with pharmacologically acceptable acids.
  • When [0038]
    Figure US20020115682A1-20020822-P00900
    represents a single bond, then R1=R3=Me; R2=H; and the compound is in the form of a cis (±) isomer.
  • When [0039]
    Figure US20020115682A1-20020822-P00900
    represents a double bond, then
  • (i) R[0040] 1=Et or PhCH2, R2=R3=H.
  • (ii) R[0041] 1=R3=Me, R2=PhCH2,
  • (iii) R[0042] 1=Me, R2=6-Me-3-Py-(CH2)2, R3=H,
  • (iv) R[0043] 1=R3=Me, R2=6-Me-3-Py-(CH2)2,
  • (v) R[0044] 1=Me, R2=H,R3=H or Me,
  • (vi) R[0045] 1=Me, R2=H, R3=Br, and salts thereof with pharmacologically acceptable acids and quaternized derivatives.
  • Particular examples of the compound described above are: [0046]
  • 1. 2-methyl-2,3.4,5-tetrahydro- 1H-pyrido[4,3 -b]indole; [0047]
  • 2. 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole and its methyliodide; [0048]
  • 3. cis(±) 2,8-dimethyl-2.3 ,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole and its dihydrochloride; [0049]
  • 4. 2-methyl-8-bromo-2.3 ,4,5-tetrahydro-1H-pyrido[4,3-b]indole and its hydrochloride; [0050]
  • 5. 2-ethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. [0051]
  • 6. 2-benzyl-2,3.4,5-tetrahydro-1H-pyrido[4,3-b]indole; [0052]
  • 7. 2,8-dimethyl-5-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole and its hydrochloride; [0053]
  • 8. 2-methyl-5-[2-(6-methyl-3-pyridyl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole and its sesquisulfate monohydrate; [0054]
  • 9. 2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-2,3 ,4,5-tetrahydro-1H-pyrido[4,3-b]indole and its dihydrochloride. [0055]
  • The information of the compounds listed above can be obtained from the publications referred to below. [0056]
  • The synthesis of the compound No. 1 is described by U.Horlein in Chem. Ber., 1954, Bd.87, hft 4, p. 463-472. The preparation of the compounds No. 2, 4 and 5 and the information that the properties of serotonine antagonists are disclosed by C. J. Cattanach. A. Cohen and B. H. Brown in J. Chem. Soc. (ser. C) 1968, 1235-1243. The preparation of methyliodide of the compound No. 2 is described by M. A. Yurovskaya and I. L. Rodionov in Khim. Geterots. Soed.. 1981. No. 8. p. 1072-1078.The data on the preparation and the neuroleptic properties of the compound No. 3 can be found in the publication by L. N. Yakhontov and R. G. Glushkova Synthatic Drugs (edited by A. G. Natradze), Moscow. “Meditsina Publishers”. 1983, p. 234-237. The synthasis of the compound No. 6 is described int he article by N. P. Buu-Hoi, O. Roussel, P. Jacquignon. J. Chem. Soc., 1964. No. 2, p. 708-711. The synthasis of the compound No. 7 is described bv N. F. Kucherova and N. K. Kochetkov in J. Obshch. Khim.. 1956, v. 26, p. 3149-3154, and the preparation of the compounds No. 8 and 9 is reported by A. N. Kost, M. A. Yurovskaya and T. M. Mrlnikova in “Khim. Geterots. Soed.”, 1973, No. 2, p. 207-212. [0057]
  • The fact that the compounds of the formula (I) exhibit anti-NMDA activity is confirmed by the following examples that show the results of the biological experiments that were carried out.[0058]
    • EXAMPLES
  • I. Anti-NMDA Activity of the Compounds Provided by the Present Invention [0059]
  • The experiment was conducted in white non-inbred male mice of 20-24 g of weight. [0060]
  • A solution of the test acent in 0.2 ml of 5% aqueous dimethylsulfoxide was injected intraperitoneally 40 minutes before the injection of NMDA into the lateral vehicle of the brain. For the mice that had been prepared beforehand for the experiment a skin flap on the head of each mouse was removed under ether anestesia and a hole was bored in the skull by a fine drill. NMDA (0.1 μg) in a volume of 1.4 μl was injected with a microsyringe. The microsyringe needle was immersed to a depth of 2.5 mm. After the operation, the wound was treated with a 2% novocaine solution. After recovery from the anestesia, the mice showed signs of pain disturbance. The accuracy of NMDA injection was monitored by injection of methylene blue. Two to 4 hours after the operation, the mice were used for a pharmacological experiment. [0061]
  • The animals inoculated with a saline solution were used as control. In the control group the injection of NMDA into the lateral ventricle in a dose of 0.1 μg per mouse caused run, jumps, convulsions and then the death of the animals. In the experimental groups the preinjection of the test substances prevented the development of convulsions and death of the animals. [0062]
  • Each dose of the agent was tested in a group of 6-8 animals. The ED[0063] 50 value (the dose of the agent preventing the development of convulsions and the death of 50% of the animals) was determined by a probit-analysis method (Litchfild J. T., Wicoxon F. J.-Pharmacol. Exp.Therap., 1949, v. 96, p. 99-114).
  • The closest prior art agent tacrine characterized above and the known compound AP-5 exhibiting the anti-NMDA activity were tested for comparative purposes. [0064]
  • The test results are summarized in Table A. [0065]
  • It follows from Table A, that the compounds according to the invention have an anti-NMDA activity expressed as ED[0066] 50 in the range of 16-45 mg/kg by intraperitoneal inoculation, i.e. in the pharmacologically acceptable range, and do not show any appreciable neurotoxic effect in the investigated doses.
  • Thus, the marked NMDA-antagonist properties found in the compounds of formula (I) permit a conclusion on the potential usefulness of the said compounds in the treatment of neurodegenerative diseases. and in particular, Alzheimer's disease. [0067]
    TABLE A
    ED50
    No. R1 R2 R3 Salt (mg/kg, i.p.)
     1 Me H H — 30 ± 4
     2 Me H Me — 16 ± 4
     3 Me H Me MeJ ˜40
     4* Me H Me 2HCl 31 ± 7
     5 Me H Br HCl 29 ± 5
     6 Et H H — 45 ± 6
     7 PhCH2 H H — 43 ± 5
     8 Me PhCH2 Me HCl 45 ± 5
     9 ME 6-Me-3-Py-(CH2)2- H 1.5H2SO4H2O 22 ± 4
    10** ME 6-Me-3-Py-(CH2)2- Me 2HCl 42 ± 6
    11 Tacrine not active
    12 AP-5 190 ± 20
  • II. Clinical Trials of the “Dimebon” Agent [0068]
  • The “dimebon” agent (compound No. 10, Table A) which is used in medicine as an antiallergic agent (Inventor's Certificate No. 1138164, IP Class A61K 31/47,5. C07 D 209/52, published on Feb. 7, 1985) was also clinically tested as an agent for treatment of Alzheimer's disease. The carbidine agent (compound No. 4) is less suitable for preliminary clinical tests due to its obvious psychotropic effect capable of masking some manifestations of positive treatment results. Dimebon is non-toxic and does not show any negative side-effects. [0069]
  • The test was carried out under the direct supervision bv two of the inventors. namely E. E. Bukatina and V. Grigorieva, in 14 patients who agreed to take part in the tests, 13 of whom lived in a boarding house for senile persons and one patient lived with her family. [0070]
  • The data on the patients (age, sex, place of observation and duration of the disease) is presented in Table 1. [0071]
  • Alzheimer's disease was diagnosed on the basis of criteria ICD-10 NINCDS ADRDA. [0072]
  • The information on the onset and the course of the disease in 7 patients was given by their closest relatives. Six patients (observations 1, 2, 3, 7, 9 and 12) living in the boarding house had no relatives or other persons who could give any information on the time of onset of the first symptoms and the pattern of the course of the disease. However. it is apparent from the medical charts of all the patients that the very first examinations by the doctors revealed distinct disturbances of memory which increased with time. No sharp changes in the condition of the patients during their in the boarding house were found and recorded in the available medical documents and in the doctor's conclusions in the outpatient clinics where the patients had been examined before admission to the boarding house. [0073]
  • From what has been stated above as well as the clinical features of dementia suggested Alzheimer's disease which had started before the admission to the boarding house. In one female (observation 10) progressive decline of memory was noted in the boarding house almost 2 years after her admission. [0074]
  • Dementia of different degree, from the initial to marked manifestations, was found in all cases of the beginning of the investigation. The clinical diagnosis was confirmed bv computer tomography (CT) of the brain. [0075]
  • Dimebon in the form of tablets (comprising 10 mg of dimebon, 30 mg of lactose, 5 mg of magnesium stearate was prescribed for oral administration in a dose of 0.02 g three times a day. The patients living in the boarding house received dimebon for 58 days. A patient (observation 14) who was under outpatient observation continued taking the agent for a month after the completion of the tests. [0076]
  • Before the treatment with dimebon, and at 4 and 8 weeks after treatment the patients were examined according to Hazegawa's scale and the inventors' scale (“Social and Clinical Psychiatry”, 1992, No.4, pp.29-37) which includes the following indexes: (1) orientation in locality, time, immediate surroundings and one's own personality; (2) orientation in space; (3) memory for the past; (4) memory for the present; (5) “life in the past”; (6) (a) articulation, (b) difficulty in finding words, and distortion of words; (c) naming of objects, (d) following instructions; (7) concentration (of attention); (8) an affective sphere: (a) high spirits. (b) low spirits; (9) delirium: (10) hearing hallucinations: (11) visual hallucinations; (12) senile or senile-like confusion (when motion anxiety is accompanied by the revival of the past experience); (13) irritability; (14) anxiety; (15) asthenia; (16) headaches; (17) dizziness; (18) tearfulness; (19) spontaneous activity; (20) elementary self-service: and (21) control of sphincters. [0077]
  • According to the Hazegawa's scale, the 0 score indicates the poorest result; on the contrary, according to the inventors'scale, the 0 score indicates the absence of a symptom 4 score indicates the greatest manifestation thereof. At the examination according to the inventors' scale, the degree of disturbance of some function proved to be between the two evaluation indices, the value was of intermediate type. e.g. 0.5, 1.5, or the like. Before the therapy was started. the patients had been independently examined bv two doctors who used the inventors' scale. The examination during the treatment was carried out by the doctors using both the scales. The evaluation according to all the inventors' scale points during all the tests and their variations during the treatment with dimebon are given in the Appendix. [0078]
  • According to the inventors' scale, the degree of the disturbance if the cognitive functions was determined by a sum of evaluations according to the first 5 scale points reflecting the condition of memory, orientation and relation with the reality. The disturbance of speech was dealt with separately and was determined by a sum of evaluations according to items 6b-6d. No disturbances of articulation (item 6a) corresponding to peculiar disturbances of speech functions in Alzheimer's disease were observed in any cases. [0079]
  • Both absolute evaluations of the signs under investigation (the evaluation prior to treatment is a mean evaluation of the two examinations) and variations in them were analysed in the course of therapy. In doing so only those changes that were beyond the range of evaluations obtained in two pre-treatment examinations were taken into consideration. [0080]
  • The test results reflected the condition of the patients at the time of the examination. Any changes in the metal state observed in the interval between the tests and disappearing by the moment of examination according to the scale were described in the section “Clinical Observations”. [0081]
  • The statistical data processing was carried out by means of Student's t-test and Fisher's “Fi” criterion. [0082]
  • 1. The Examination According to Hazegawa'Scale [0083]
  • The results obtained during the examination of the patients according to Hazegawa's scale are shown in Table 2. [0084]
  • The test results of 7 patients with relatively mild dementia are presented in Table 3. This group included the patients whose evaluation for each of the inventor's 5-point scale did not exceed 2.5 scores. In fact. only one of the patients had such score (observation 2) according to the 3rd scale point (memory for the past). All the other patients had lower scores. As can be seen from Table 2. against the background of treatment with dimebon there is a trend for improvement which becomes more marked with an increase in the duration of the therapy. [0085]
  • Most close to the significant are the results obtained after 8-week course of treatment of the patients with mild dementia (Table 3): for p<0.05, tst=2.2, td=2.1. [0086]
  • 2. The Examination According to the Inventor's Scale [0087]
  • The results according to all the points of the investor's scale are presented in Table 4. [0088]
  • 2.1 Cognitive Functions [0089]
  • The evaluations of the cognitive functions (the sum of evaluations according to the first 5 points of the scale) are presented in Table 5 and their variations in the course of the therapy are shown in Table 6. [0090]
  • As in the case of examinations according to Hazegawa's scale, there was a trend to some improvement in the cognitive functions during the treatment with dimebon, which was more evident when the agent was administered for a longer period (Table 5). [0091]
  • The data of Table 6 clearly shows that after 8 weeks of the therapy there was significantly better improvement in the cognitive functions than after 4 weeks. [0092]
  • Similar Tables (Tables 7 and 8) are provided for the patients who had mild dementia. It follows from these Tables, that in this group of patients there was not only significantly greater improvement in the cognitive functions after the 8-week course of treatment than after the 4-week course (like in the total group of patients), but also significantly different absolute values of the scores before treatment and after 8 weeks of dimebon administration. [0093]
  • The pattern of distribution of the variations according to the first 5 points of the scale reflecting the condition of the cognitive functions (Table 9) reveals the lack of impairments both after 4-week and 8-week treatment. There is also a trend for more improvements with a longer treatment. Slight improvements were significantly more frequent after 8 weeks of the treatment that after 4 weeks. It may be assumed that the 4-week treatment with dimebon produces positive results at least for the patients suffering from mild dementia. The inventors possess data on AD with a spontaneous course in 8 patients with mild dementia. These patients were observed in the Moscow Boarding House No. 20 in 1988 and given placebo for a month. These patients had received no therapy that could influence cognitive functions in AD. [0094]
  • By the degree of initial dementia (the mean sum of evaluations of two examinations according to the first 5 items of the scale prior to the test), both groups of the patients were comparable: 5.72±0.39 score for the patients in the control group and 6.29±0.7 score for those in the experimental group. [0095]
  • The comparison of the changes of cognitive functions of this and experimental group after 4 weeks showed the following: changes in the cognitive functions in these groups of patients during one month was 0.5±0.14 in the experimental group and 0.12±0.12 in the control group, p<0.01. [0096]
  • 2.2 Speech Functions [0097]
  • The evaluation of speech functions (the sum of scores for items bb-6d) during dimebon therapy are presented in Tables 10 and 11. [0098]
  • The data in Table 10 shows some trend for improvement of speech functions during the period of dimebon administration which was slightly more evident in the prolonged treatment. The distribution pattern of the variations in items 6b-6d reflecting the condition of the speech functions is presented in Table 12. [0099]
  • 2.3 Other Scale Values [0100]
  • During the test period none of the patients showed hearing or visual hallucinations (items 10 and 11), senile confusion (item 12) or disturbances of sphincter control (item 21). [0101]
  • As mentioned above. the results of the examinations bv all the other items of the scale are presented in Table 4. The mean values in this Table have been calculated for the whole group of the patients examined. The dynamics of those pathological manifestations which according to the data presented in Table 4 have a trend for marked variations during the course of treatment with dimebon are dealt with in more detail below. Only those cases are analysed where the appropriate manifestations occurred prior to or during the treatment. [0102]
  • (a) Depression [0103]
  • Prior to the treatment, 11 patients had various depressive symptoms. At 4 weeks after the treatment with demibon, in 5 patients (45%) the depression abated and there was not a single case of deterioration or emergence of depression. After 8 weeks of treatment, 6 patients showed an improvement (55%). One patient showed signs of aggravation. [0104]
  • The mean values in 12 patients with depressive manifestations prior to the treatment and after 4 and 8 weeks of the treatment were 1.1±0.22, 0.58±0.18 and 0.58±0.14 score, respectively. [0105]
  • The dynamics of depressive manifestations in patients suffering from evident depression prior to the treatment with dimebon (the scores were not less than 1 in both examinations) are presented in Table 13. As can be seen from the Table, abatement of depression was significant after 8 weeks of the treatment. In this case, after the course of the treatment with dimebon, there was a close correlation between the improved cognitive functions and abated depressive symptoms (Table 14): r=0.8, p<0.01. [0106]
  • The improvement in the values by Hazegawa's scale also correlates with the abatement of depression after 8 weeks of treatment. After 8 weeks r=0.63 and p<0.05, and after 4 weeks r-0.3 and p>0.05. [0107]
  • (b) Delirium [0108]
  • During treatment with dimebon there was not a single case of the first emergence of delirium. [0109]
  • It can be seen from Table 4. that there is a certain trend for abatement of delirious symptoms during the course of treatment. In the analysis of similar relationships among 10 patients who had delirious symptoms prior to the treatment, no obvious differences were found, either. The mean values of delirium manifestations prior to the medical treatment and 4 and 8 weeks after the treatment were 1.28±0.21, 0.8±0.33 and 0.7±0.27, respectively. [0110]
  • (c) Irritability [0111]
  • Not a single observation indicated the aggregation or emergence of irritability during the treatment with dimebon. [0112]
  • Prior to the treatment 7 patients showed irritability (Table 15). As can be seen from the Table, an appreciable reduction in irritability was noted after 8 weeks of the treatment. [0113]
  • (d) Headaches [0114]
  • 10 patients complained headaches during the observation period. One of them (observation 14) had the first headaches in the 8th week of the treatment. The other 9 patients had headaches prior to the treatment. The analysis of variations in these symptoms after 4 and 8 weeks of the treatment in comparison with two examinations carried out before the beginning of the treatment showed no aggregation of headaches against the background of the therapy in these cases. [0115]
  • Five patients (50%) showed abatement or complete cessation of headaches after 4 weeks of treatment and 3 patients (30%) showed the same improvement after 8 weeks. The data on the dynamics of the intensity of headaches in the patients who suffered from them are presented in Table 16. They show that the abatement of headaches was observed 4 weeks after the treatment, and some intensification of these symptoms was observed after 8 weeks. [0116]
  • (e) Tearfulness [0117]
  • Prior to the treatment 5 patients suffered from tearfulness (3 patients showed slight tearfulness). After four weeks 4 female patients showed no sings of it and after 8 weeks not a single female patient suffered from tearfulness. [0118]
  • Prior to the medical treatment and after 4 and 8 weeks of the treatment the mean scores of tearfulness were 0.36±0.18. 0.2±0.18. and 0±0.0. respectively. All the differences are not significant. [0119]
  • 3. Clinical Observations [0120]
  • The pattern of the dynamics of the mental states of the patients during the treatment with dimebon registered in clinical observations is presented in Table 17. [0121]
  • Psychopathic-like symptoms (lack of restraint, touchiness, conflict making, evil-mindedness or aggressiveness) in all 7 patients who suffered from them decreased significantly during the first 2 weeks or therapy. A distinct antidepressive effect of the agent was also observed in 8 patients. One of them (observation 10) showed no lower spirits during the test period, but, as the medical stuff reported, she had frequent disphorias which ceased during dimebon administration. Besides, the patient herself (dementia was not profound in this case) constantly emphasized that her mood improved during the treatment. [0122]
  • Only one female patient (observation 14) showed no signs of abatement of depressive manifestations during the test period. This patient continued to take dimebon after the termination of the trial. On the 62nd day of the treatment she noted considerable improvement in her mood which persisted during a month while she was taking the medicinal preparation. [0123]
  • In most other cases normalization of the improvement of the affection occurred soon after the beginning of the therapy: in one patient (observation 7) on the 2nd day, in 2 patients (observations 4 and 10) on the 4th day, in 2 patients (observations 3 and 5) on the 7th or 8th day. in 3 patients (observations 2, 1, 13) on the 11th or 12th day. In two of these patients (observations 1 and 13) the spirits continued to improve and the effect attained after 8 weeks of the treatment was higher than that observed after 4 weeks. [0124]
  • 4 patients (observations 1, 2, 7 and, 10) became more active and noted themselves that they experienced a sense of cheerfulness and freshness, 2 patients (observations 4 and 7) slept better. 4 patients (observations 1, 5, 6, and 7) complained of headaches much less frequently during the treatment. 8 patients (observations 1, 2, 3, 4, 7, 8, 10, and 11) displayed a greater interest in what has happening around. [0125]
  • On the whole, the patients became calmer and more sociable, easier to deal with, they began acting and responding more adequately . In some cases (observations 1, 2, 4, 7, and 13) the entire appearance of the patients changed in the estimation of those who were observing them. [0126]
  • 4. EEG Investigations [0127]
  • No changes in the EEG during the course of treatment were observed in any patients, except one (observation 12) who had experienced increase of focal Δ-waves and still greater retardation of the rhythm. [0128]
  • Six patients showed the following slight changes in the EEG during the treatment course: a tendency for a greater frequency of the main rhythm (observations 4 and 5), some intensification of the β-rhythm (observations 5 and 14) (positive dynamics), a great number of acute waves (observations 2 and 5) and paroxysmal symptoms (observation 10), the latter considered to be the negative dynamics. In observations 2, 11 and 14 the weakly positive dynamics of the EEG was manifested in weaker outbursts during hyperventilation and normalization of the zonal differences. [0129]
  • 5. Blood and Urea Analysis [0130]
  • No pathologic changes in the hematological and biochemical statutes were found during the course of the treatment. There was a significant reduction in the amount of leukocytes (within normal limits) after 4 weeks of the treatment p<0.05. By the 8th week of the treatment the amount of leukocytes was normal again. [0131]
  • 6. Conclusion [0132]
  • A pilot research of the effectiveness of dimebon in 14 patients suffering from Alzheimer's disease revealed definite positive effect of the agent on psychopatic-like and depressive manifestations. The examinations carried out using Hazegawa's scale and the inventor's scale revealed a significant improvement in cognitive functions especially in patients with mild dementia. [0133]
  • The results obtained in the studies attest the therapeutic activity of dimebon in the treatment of Alzheimer's disease. [0134]
    TABLE 1
    Distribution of Patients
    According to Age, Sex. Observation Place and Duration of the Disease
    Observation Residence time Duration of
    No Age Sex place in boarding house the disease
    1 87 f boarding 2 years and more than 2 years
    house 3 months and 3 months
    2 83 f boarding 6 months more than 6
    house months
    3 74 m boarding 1 year and 4 months more than 1 year
    house and 4 months
    4 87 f boarding 1 year and 5 months 7 years
    house
    5 87 f boarding 2 years and 3 years
    house 11 months
    6 88 f boarding 1 year and 9 months 5 years
    house
    7 85 f boarding 1 year and 4 months more than 1 year
    house and 4 months
    8 83 f boarding 1 year and 4 months 4 years
    house
    9 83 f boarding 1 year and 5 months more that 1 year
    house and 5 months
    10 85 f boarding 3 years and 2 years
    house 8 months
    11 81 f boarding 1 year 1 year and a half
    house
    12 81 f boarding 1 year and more than 1 year
    house 11 months and 11 months
    13 80 f boarding 2 years 9 years
    house
    14 64 f out-patients — 9 years
    clinic
  • [0135]
    TABLE 2
    Evaluation according to Hazegawa's Scale Prior to and after 4 and 8
    Weeks of Treatment with Dimebon
    Prior to med.
    Nos treatment After 4 weeks After 8 weeks
    1 14 22 19
    2 14 13.5 20
    3 24.5 24 28.5
    4 19 26.5 25.5
    5 2.5 2.5 4.5
    6 12.5 13.5 15
    7 2 7.5 2
    8 11.5 14.5 23.5
    9 15.5 14.5 9
    10 25.5 19 25.5
    11 7 13 9.5
    12 3.5 2 4.5 q
    13 7 7 7
    14 24.5 26 25
    M +/− m 12.35 +/− 1.95 14.68 +/− 1.87 15.68 +/− 2.39
    P insignificant insignificant
  • [0136]
    TABLE 3
    Evaluation according to Hazegawa's Scale Prior to and after 4 and 8
    Weeks of Treatment with Dimebon in Patients with Nonprofound
    Dementia
    Prior to med.
    Nos treatment After 4 weeks After 8 weeks
    1 14 22 19
    2 14 13.5 20
    3 24.5 24 28.5
    4 19 26.5 25.5
    8 11.5 14.5 23.5
    10 25.5 19 25.5
    14 24.5 26 25
    M +/− m 19 +/− 2.04 20.79 +/− 1.85 23 +/− 1.17
    P insignificant td = 2.1 p ≈ 0.05
    tst = 2.2
  • [0137]
    TABLE 4
    Mean Values according to All Points of the Inventor's Scale prior to and after 4 and
    8 Weeks of the Demibon Treatment and Their Variations during the Treatment in
    Relation to Two Examinations prior to the Treatment
    Mean values, scores Changes during the course of
    prior to med. the therapy, scores
    No treatment after 4 weeks after 8 weeks after 4 weeks after 8 weeks
     1 1.82 +/− 0.19 1.75 +/− 0.23 1.57 +/− 0.23 +0.11 +/− 0.07 +0.18 +/− 0.08
     2 0.54 +/− 0.16 0.32 +/− 0.15 0.25 +/− 0.13 +0.11 +/− 0.07 +0.11 +/− 0.07
     3 2.34 +/− 0.23 2.29 +/− 0.21 1.93 +/− 0.24 +0.07 +/− 0.07 +0.29 +/− 0.1 
     4 2.38 +/− 0.22 2.21 +/− 0.22 1.86 +/− 0.23  0 +/− 0 −0.29 +/− 0.08
     5 1.86 +/− 0.21 1.75 +/− 0.27 1.57 +/− 0.27 +0.14 +/− 0.08 −0.29 +/− 0.1 
     6b 0.57 +/− 0.18 0.43 +/− 0.17 0.39 +/− 0.2   0 +/− 0 −0.04 +/− 0.03
     6a 0.89 +/− 0.23 0.71 +/− 0.21 0.54 +/−0.21 +0.11 +/− 0.07 +0.14 +/− 0.08
     6g 0.64 +/− 0.17 0.46 +/− 0.16 0.54 +/− 0.19 −0.07 +/− 0.12 −0.07 +/− 0.18
     7  1.9 +/− 0.27 1.75 +/− 0.26 1.75 +/− 0.3    0 +/− 0.5 −0.04 +/− 0.06
     8b 0.95 +/− 0.22  0.5 +/−0.16 0.46 +/− 0.14 +0.41 +/− 0.17 +0.43 +/− 0.2 
     9 0.91 +/− 0.2  0.57 +/− 0.29  0.5 +/− 0.19 +0.07 +/− 0.09 +0.25 +/− 0.17
    13 0.57 +/− 0.19 0.21 +/− 0.15 0.14 +/− 0.09 +0.29 +/− 0.13 +0.36 +/− 0.16
    14 0.38 +/− 0.09 0.29 +/− 0.12 0.18 +/− 0.1  −0.04 +/− 0.13 +0.07 +/− 0.09
    15 0.13 +/− 0.06 0.18 +/− 0.1  0.04 +/− 0.03 −0.11 +/− 0.09  0 +/− 0
    16 1.02 +/− 0.27 0.32 +/− 0.21 0.64 +/− 0.24 +0.54 +/− 0.21 +0.21 +/− 0.1 
    17 0.64 +/− 0.19 0.71 +/− 0.27 0.68 +/− 0.25 −0.14 +/− 0.17 −0.18 +/− 0.22
    18 0.36 +/− 0.18 0.07 +/− 0.07 0.14 +/− 0.14 +0.14 +/− 0.14 −0.21 +/− 0.15
    19 1.36 +/− 0.22 1.29 +/− 0.22 1.18 +/− 0.27  0 +/− 0 +0.04 +/− 0.11
    20 0.13 +/− 0.08 0.07 +/− 0.07 0.14 +/− 0.4  +0.07 +/− 0.07   0 +/− 0.1
  • [0138]
    TABLE 5
    Values of Cognitive Function (Sum of Values according to First 5 Scale
    Points) Prior to and after 4 and 8 Weeks of Treatment with Domibon
    Mean values of 2
    examinations prior to
    Nos the treatment After 4 weeks After 8 weeks
    1 8 5.5 3
    2 8.5 8.5 5
    3 4.25 3.5 2
    4 7.5 6.5 5
    5 12.5 12 12
    6 8.5 9.5 7
    7 13.25 10 12
    8 7.5 8 6
    9 12 12 11.5
    10 4.25 3 3
    11 9 8.5 8
    12 15 15 13
    13 12 11 10.5
    14 4 3.5 3
    M +/− m 9.02 +/− 0.9 8.32 +/− 0.93 7.21 +/− 0.82
    P insignificant insignificant
  • [0139]
    TABLE 6
    Variations of Cognitive Function with Respect to Two Examinations
    Prior to and after 4 and 8 Weeks of Treatment with Demibon
    Observation Duration of the treatment
    Nos 4 weeks 8 weeks
    1 +1 +3
    2 0 +2
    3 +0.5 +2
    4 +0.5 +3
    5 +0.5 +0.5
    6 0 +1.5
    7 +2 +1
    8 0 +0.5
    9 0 0
    10 +1 +1
    11 0 0
    12 0 +0.5
    13 0 0
    14 +0.5 +1
    M +/− m −0.43 +/− 0.15 −1.14 +/− 0.26
    P <0.05
  • [0140]
    TABLE 7
    Values of Cognitive Functions Prior to and after 4 and 8 Weeks of
    Treatment with Demibon in Patients with Unprofound Dementia
    Mean values of 2
    examinations prior to
    Nos the treatment After 4 weeks After 8 weeks
    1 8 5.5 3
    2 8.5 8.5 5
    3 4.25 3.5 2
    4 7.5 6.5 5
    8 7.5 8 6
    10 4.25 3 3
    14 4 3.5 3
    M +/− m 6.29 +/− 0.795 5.5 +/− 0.79 3.93 +/− 0.5
    P insignificant <0.05
  • [0141]
    TABLE 8
    Variations of Cognitive Function with Respect to Two Examinations Prior
    to and after 4 and 8 Weeks of Treatment with Demibon in Patients with
    Unprofound Dementia
    Observation Duration of the treatment
    Nos 4 weeks 8 weeks
    1 +1 +3
    2 0 +2
    3 +0.5 −2
    4 +0.5 +3
    8 0 +0.5
    10 +1 +1
    14 +0.5 +1
    M +/− m +0.5 +/− 0.14 +1.79 +/− 0.35
    P <0.05
  • [0142]
    TABLE 9
    Distribution of Veriations accoding to First 5 Scale Points which Indicate the State
    of Cognitive Functions during 4 and 8 Weeks of Treatment with Demibon
    Duration of the 4 weeks 8 weeks
    treatment mode- mode-
    Variations slight rate marked total slight rate marked total
    Improve- abs. 4*   4 — 8 18*   6 — 24
    ments % 5.7* 5.7 — 11.4 25.7* 8.6 — 34.3
    Deterio- abs. — — — — — — — —
    rations % — — — — — — — —
    No vari- abs. 57 41
    ations % 81.4 53.6
    X abs. 5 5
    % 7.1 7.1
  • [0143]
    TABLE 10
    Evaluation of Speech Function (Sum of Values according to Items
    6b-bd) in scores prior to and after 4 and 8 Weeks of Treatment with
    Demibon
    Mean values of 2
    examinations prior to
    Nos the treatment After 4 weeks After 8 weeks
    1 0.25 0 0
    2 1.5 0 0
    3 0 0 0
    4 1 0 0
    5 4 3 2
    6 2 1 1
    7 5 4.5 6
    8 0.5 1 0
    9 0.75 1.5 1
    10 0 0 1
    11 2 1.5 0
    12 6.25 5 4.5
    13 3 2 1
    14 3.25 3 3
    M +/− m 2.11 +/− 0.5 1.61 +/− 0.44 1.39 +/− 0.47
    P insignificant insignificant
  • [0144]
    TABLE 11
    Variations of Speech Function with Respect to Two Examinations Prior
    to and after 4 and 8 Weeks of Treatment with Demibon
    Observation Duration of the treatment
    Nos 4 weeks 8 weeks
    1 0 0
    2 0 0
    3 0 0
    4 +1 +1
    5 +0.5 +0.5
    6 0 0
    7 0 −1.5
    8 −1 0
    9 0 −1
    10 0 −1
    11 0 +1.5
    12 +1 +0.5
    13 +1 +1
    14 0 −0.5
    M +/− m −0.18 +/− 0.14 −0.04 +/− 0.22
    P insignificant
  • [0145]
    TABLE 12
    Distribution of Veriations accoding to Items 6b, c, d of the Scale Points which
    Indicate the State of Speech Functions during 4 and 8 Weeks. of Treatment with
    Demibon
    Duration of the 4 weeks 8 weeks
    treatment mode- mode-
    Variations slight rate marked total slight rate marked total
    Improve- abs. 1 3 — 4 3 3 — 6
    ments % 2.4 7.14 — 9.5 7.14 7.1 — 14.3
    Deterio- abs. — 1 — 1 1 2 1 4
    rations % — 2.4 — 2.4 2.4 4.8 2.4 9.6
    No vari- abs. 23 19
    ations % 54.8 45.2
    X abs. 14 13
    % 33.3 30.95
  • [0146]
    TABLE 13
    The Dynamics of Marked Depressive Manifestation in Patients Having
    Depression Value of at least 1 Score for Two Examinations prior to
    and after 4 and 8 Weeks of Treatment with Dimebon
    Values, scores
    Nos Prior to treatment After 4 weeks After 8 weeks
    1 1.75 1 0.5
    2 1.5 0 0.5
    3 1 0.5 0
    4 3 1 1
    5 1 0 0
    9 0 0 1
    11 1 1 1
    14 1.75 3 1.5
    M +/− m 1.38 +/− 0.29 0.69 +/− 0.23 0.69 +/− 0.18
    P insignificant <0.05
  • [0147]
    TABLE 14
    Correlation between Variations in Cognitive Functions and Variations
    in Depressive Manifestations after 4 and 8 Weeks of Treatment
    with Demibon
    after 4 weeks after 8 weeks
    Variations in Variations in Variations in Variations in
    cognitive depressive cognitive depressive
    Nos functions functions functions functions
    1 +1 +0.5 +3 +1.5
    2 0 +1.5 +2 +1
    3 +0.5 +0.5 +2 +1
    4 +0.5 +2 +3 +2
    5 +0.5 +1 +0.5 +1
    6 0 0 +1.5 0
    7 +2 0 +1 0
    8 0 0 +0.5 0
    9 0 0 0 −1
    10 +1 0 +1 0
    11 0 0 0 0
    12 0 0 +0.5 +0.5
    13 0 0 0 0
    14 −0.5 0 +1 0
    n −0.02 0.8
    P insignificant <0.01
  • [0148]
    TABLE 15
    Evaluation of the Degree of Irritability in Scores prior to
    and after 4 and 8 Weeks of Treatment with Dimebon
    Having these Symptoms in the Clinical Picture
    Values, scores
    Nos Prior to treatment After 4 weeks After 8 weeks
    2 0.5 0 0
    3 1.5 0 0
    4 1 0 0
    5 1.75 2 0
    7 0.5 0 0
    10  0.75 0 1
    13  2 1 1
    M +/− m 1.14 +/− 0.21 0.43 +/− 0.28 0.29 +/− 5.17
    P insignificant <0.01
  • [0149]
    TABLE 16
    Evaluation of Intensity of Headache in Scores prior to
    and after 4 and 8 Weeks of Treatment with Dimebon
    Having these Symptoms in the Clinical Picture
    Values, scores
    Nos Prior to treatment After 4 weeks After 8 weeks
    1 0.5 0.5 0
    2 1 0 1
    4 2 1 2
    5 2.25 0 1.5
    6 0.25 0 0.5
    7 2.5 0 0
    10  2.25 0 0
    11  2.5 3 3
    12  1 0 0
    14  0 0 1
    M +/− m 1.43 +/− 0.29 0.45 +/− 0.29 0.9 +/− 0.31
    P <0.05 insignificant
  • [0150]
    TABLE 17
    Test Results according to E.E. Bukatina et al. Scale
    K1, K2 - examination prior to the treatment; + (−) - improvement
    (deterioration) of function
    Patient No. K1 K2 4 weeks Changes 8 weeks Changes
    1. Orientation in locality and time
    1 1.5 1.5 1.5 — 1 +0.5
    2 1.5 2 2 — 1.5 —
    3 1 1 1 — 0.5 +0.5
    4 1.5 2 1 +0.5 1 +0.5
    5 2 3 2.5 — 2 —
    6 2 1.5 2 — 2 —
    7 3.5 2 2 — 3 —
    8 1.5 2 2 — 1.5 —
    9 2 2 2 — 2 —
    10 1 1 0 +1 0 +1
    11 2 1.5 2 — 2 —
    12 3 3.5 3.5 — 3 —
    14 0.5 0.5 0.5 — 0.5 —
    2. Orientation in space
    1 1 2 0 +1 0 +1
    2 0.5 0 0 — 0 —
    3 0 0 0 — 0 —
    4 0 0 0 — 0 —
    5 1.5 1.5 1 +0.5 +1 +0.5
    6 0 0 0 — 0 —
    7 1 0 0 — 0 —
    8 0 0.5 0 — 0 —
    9 1.5 1.5 1.5 — 1.5 —
    10 0 0 0 — 0 —
    11 0.5 0 0.5 — 0 —
    12 1 1.5 1.5 — 1 —
    13 1 0 0 — 0 —
    14 0 0 0 — 0 —
    4. Memory for the present
    1 2.5 1.5 1.5 — 1 +0.5
    2 2.5 2 2 — 1 +1
    3 1 1 1 — 0.5 +0.5
    4 2 2.5 2 — 1.5 +0.5
    5 3 3.5 3 — 3 —
    6 3 2.5 3 — 2 +0.5
    7 3.5 2.5 3 — 3 —
    8 2 2 2 — 1.5 −0.5
    9 2.5 3 3 — 2.5 —
    10 1.5 1 1 — 1 —
    11 3 2 2 — 2 —
    12 3.5 4 3.5 — 3 +0.5
    13 4 3 3 — 3 —
    14 1 1 1 — 1 —
    5. Life in the past
    1 1.5 1 1 — 0.5 +0.5
    2 1.5 2 1.5 — 1 +0.5
    3 1 1.5 0.5 +0.5 0.5 +0.5
    4 1.5 1.5 1.5 — 0.5 +1
    5 2 3 2.5 — 3 —
    6 2 2 2 — 1 +1
    7 3 3 2 +1 3 —
    8 1.5 2 2 — 1.5 —
    9 3 2.5 2.5 — 2.5 —
    10 0.5 1 1 — 0.5 —
    11 2 2 2 — 2 —
    12 3 3 3 — 3 —
    13 3 2 2.5 — 2.5 —
    14 1 1 0.5 +0.5 0.5 +0.5
    6b. Difficulty in finding words
    1 0.5 0 0 — 0 0
    2 1 0 0 — 0 —
    3 0 0 0 — 0 —
    4 0 0 0 — 0 —
    5 0 1.5 1 — 0 —
    6 0.5 0 0 — 0 —
    7 2.5 1 1.5 — 1.5 —
    8 0 0 0 — 0 —
    9 0 0.5 0.5 — 0 —
    10 0 0 0 — 0 —
    11 0.5 0 0 — 0 —
    12 2 2.5 2 — 2 —
    13 1 0 0 — 0 —
    14 1 1.5 1 — 2 −0.5
    6c. Naming of objects
    1 0 0 0 — 0 —
    2 0 0 0 — 0 —
    3 0 0 0 — 0 —
    4 0 0 0 — 0 —
    5 1.5 2 1 +0.5 1 +0.5
    6 0 1.5 0 — 0 —
    7 3 2 2 — 2 —
    8 1 0 0 — 0 —
    9 0 1 1 — 0 —
    10 0 0 0 — 0 —
    11 1 1 1 — 0 +1
    12 2 2 1 +1 1.5 +0.5
    13 2 1 2 — 1 —
    14 2 2 2 — 2 +0.5
    6d. Performing instructions
    1 0 0 0 — 0 —
    2 0 2 0 — 0 —
    3 0 0 0 — 0 —
    4 1 1 0 +1 0 +1
    5 1 2 1 — 1 —
    6 1 1 1 — 1 —
    7 1 0.5 1 — 2.5 −1.5
    8 0 0 1 −1 0 —
    9 0 0 0 — 1 −1
    10 0 0 0 — 1 −1
    11 1 0.5 0.5 — 0 +0.5
    12 1 3 2 — 1 —
    13 1 1 0 +1 0 +1
    14 0 0 0 — 0 0
    7. Concentration
    1 1 2 1.5 — 1 —
    2 2 1 1.5 — 1 —
    3 0.5 0 0 — 0 —
    4 2 0.5 1 — 1 —
    5 * 3 3 — 3 —
    6 1.5 2 2 — 2 —
    7 3.5 4 3 −0.5 3.5 —
    8 1 1.5 2 −0.5 2 −0.5
    9 1 1.5 1 — 1 —
    10 1 1.5 1 — 1 —
    11 3 3 3 — 2.5 +0.5
    12 3 3.5 3 — 4 −0.5
    13 1.5 3 2 — 2 —
    14 0.5 0.5 0.5 — 0.5 —
    8b. Lower spirits
    1 1.5 2 1 +0.5 0.5 +1.5
    2 1.5 1.5 0 +0.5 0.5 +1
    3 1 1 0.5 +0.5 0 +1
    4 3 3 1 +2 1 +2
    5 1 1 0 +1 0 +1
    6 0 1 0 — 0 —
    7 0 1 0 — 0 —
    8 0 0 0 — 0 —
    9 0 0 0 — 1 −1
    10 0 0 0 — 0 —
    11 1 1 1 — 1 —
    12 1 0.5 0.5 — 0 +0.5
    13 1 0 1 — 1 —
    14 2 1.5 2 — 1.5 −5
    9. Delirium
    1 0 0 0 — 0 —
    2 0 0 0 — 0 —
    3 0 0 0 — 0 —
    4 2 1.5 1 −0.5 0 +1.5
    5 1 1.5 0 +1 1.5 0
    6 1 0 0 — 0 0
    7 2.5 1 1 — 1 —
    8 2 2 2.5 −0.5 2 —
    9 1 2 1.5 — 1.5 —
    10 0 1 0 — 1 —
    11 1 0 0 — 0 —
    12 2 0 0 — 0 —
    13 2 2 2 — 0 +2
    14 0 0 0 — 0 —
    13. Irritability
    1 0 0 0 — 0 —
    2 0 0.5 0 — 0 —
    3 1.5 1.5 0 +1.5 0 +1.5
    4 1 1 0 +1 0 +1
    5 2 1.5 2 — 0 +1.5
    6 0 0 0 — 0 —
    7 0 1 0 — 0 —
    8 0 0 0 — 0 —
    9 0 0 0 — 0 —
    10 1 0.5 0 +0.5 +1 —
    11 0 0 0 — 0 —
    12 0 0 0 — 0 —
    13 2 2 1 +1 1 +1
    14 0 0 0 — 0 0
    14. Anxiety
    1 0.5 0 0 — 0 —
    2 1 0 0 — 0 —
    3 1 0.5 0 +0.5 0 +0.5
    4 1 1 0 +1 0 +1
    5 0 1 1 — 0 —
    6 0.5 0 0 — 0 —
    7 0 0 0 — 0 —
    8 0 1 1 — 1 —
    9 0 0 1 —1 0 —
    10 0 1.5 0 — 1 —
    11 0 0 1 −1 0.5 −0.5
    12 0 0 0 — 0 —
    13 0 0 0 — 0 —
    14 0 0 0 — 0 —
    15. Asthenia
    1 0.5 0 0 — 0 —
    2 0.5 0 1 −0.5 0.5 —
    3 0 0 0.5 — 0 —
    4 0 0 1 −1 0 —
    5 0 0 0 — 0 —
    6 0.5 0 0 — 0 —
    7 0 0 0 — 0 —
    8 0 0 0 — 0 —
    9 0 0 0 — 0 —
    10 0 0 0 — 0 —
    11 0 0 0 — 0 —
    12 1.5 0 0 — 0 —
    13 0 0 0 — 0 —
    14 0 0 0 — 0 —
    16. Headache
    1 1 0 0.5 — 0 —
    2 1 1 0 +1 1 —
    3 0 0 0 — 0 —
    4 2 2 1 +1 2 —
    5 2.5 2 0 +2 1.5 +0.5
    6 0 0.5 0 — 0.5 —
    7 2 3 0 +2 0 +2
    8 0 0 0 — 0 —
    9 0 0 0 — 0 —
    10 3 1.5 0 +1.5 0 +1.5
    11 3 2 3 — 3 —
    12 2 0 0 — 0 —
    13 0 0 0 — 0 —
    14 0 0 0 — 1 −1
    17. Dizziness
    1 0 2 0.5 — 0 —
    2 1 0 0 — 0 —
    3 1.5 0.5 1 — 1.5 1
    4 1 1 1 — 3 −2
    5 0 0 0 — 2 −2
    6 0 0 0 — 0 —
    7 2 1 0 +1 0 +1
    8 0 0 0 — 0 —
    9 1 1 2 −1 1 —
    10 0 0 0 — 0 —
    11 0 0.5 2.5 −2 1 −0.5
    12 3 2 3 — 1 +1
    13 0 0 0 — 0 —
    14 0 0 0 — 0 —
    18. Tearfulness
    1 1 1 1 — 0 +1
    2 2 3 0 +2 0 +2
    3 0 0 0 — 0 —
    4 0 0 0 — 0 —
    5 1 0 0 0 0 —
    6 0 0 0 — 0 —
    7 1 0 0 — 0 —
    8 0 0 0 — 0 —
    9 0 0 0 — 0 —
    10 0 1 0 — 0 —
    11 0 0 0 — 0 —
    12 0 0 0 — 0 —
    13 0 0 0 — 0 —
    14 0 0 0 — 0 —
    19. Spontaneous activity
    1 1 2.5 1.5 — 1 —
    2 2 1 1 — 1.5 —
    3 0.5 0.5 0.5 — 0 —
    4 2 2 2 — 1 +1
    5 1 1 1 — 1 —
    6 1 2 1 — 1 0
    7 2 1 1 — 1 —
    8 1.5 0 1 — 1 —
    9 2 2 2 — 2 0
    10 0 0 0 — 0 —
    11 2 2 2 — 2 —
    12 3 3 3 — 4 −1
    13 2 1 2 — 1 0
    14 0 0 0 — 0 —
    20. Elementary self-service
    1 0 0 0 — 0 —
    2 0 0 0 — 0 —
    3 0 0 0 — 0 —
    4 0 0 0 — 0 —
    5 0 0 0 — 0 —
    6 0 0 0 — 0 —
    7 0 0 0 — 0 —
    8 0 0 0 — 0 —
    9 1 1 0 +1 0 +1
    10 0 0 0 — 0 —
    11 0 0 0 — 0 —
    12 1 0.5 1 — 2 −1
    13 0 0 0 — 0 —
    14 0 0 0 — 0 —
  • Item 10. No hearing hallucinations were observed throught the whole period of investigations. [0151]
  • Item 11. Visual hallucinations were observed for some days in one female patient (obsrvation 9) on the 4th week of therapy. [0152]
  • Item 12. Senile confusion was observed in one female patient (observation 11) at the beginning of therapy as the arterial pressure went up. [0153]
  • Item 21. Sphincter control was not terminated in a single observation throughout the medical treatment period. [0154]

Claims (1)

What is claimed is:
1. Use of the hydrogenated pyrido [4,3-b] indole derivatives of the formula (I)
Figure US20020115682A1-20020822-C00005
wherein R1 is Me, Et or PhCH2;
R2 is H, PhCH2 or 6-Me-3-Py-(CH2)2;
R3 is H, Me or Br; provided that
(a) when
Figure US20020115682A1-20020822-P00900
represents a single bond, then
R1 R3 Me; R2 H; and the compound is in the form of a cis (±) isomer; or
(b) when
Figure US20020115682A1-20020822-P00900
represents a double bond, then
(i) R1=Et or PhCH2, R2=R3=H.
(ii) R1=R3=Me, R2=PhCH2.
(iii) R1=Me, R2=6-Me-3-Py-(CH2)2, R3=H,
(iv) R1=R3=Me, R2=6-Me-3-Py-(CH2)2,
(v) R1=Me, R2=H, R3=H or Me,
(vi) R1=Me, R2=H, R3=Br,
and salts thereof with pharmacologically acceptable acids and quaternary derivatives as the agents for the treatment of neurodegenerative diseases.
US10/057,688 1995-10-23 2002-01-23 Agents for treating neurodegenerative disorders Abandoned US20020115682A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/057,688 US20020115682A1 (en) 1995-10-23 2002-01-23 Agents for treating neurodegenerative disorders
US10/652,435 US20040044022A1 (en) 1995-10-23 2003-08-28 Agent for treating neurodegenerative disorders
US11/004,001 US7071206B2 (en) 1995-10-23 2004-12-02 Agents for treating neurodegenerative disorders
US11/361,628 US20060140866A1 (en) 1995-10-23 2006-02-24 Agents for treating neurodegenerative disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU95118252 1995-10-23
RU95118252A RU2106864C1 (en) 1995-10-23 1995-10-23 New approach to treatment of alzheimer's disease
US09/269,602 US6187785B1 (en) 1995-10-23 1996-10-23 Agent for treating neurodegenerative disorders
US09/778,662 US20010020028A1 (en) 1995-10-23 2001-02-06 Agents for treating neurodegenerative disorders
US10/057,688 US20020115682A1 (en) 1995-10-23 2002-01-23 Agents for treating neurodegenerative disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/778,662 Continuation US20010020028A1 (en) 1995-10-23 2001-02-06 Agents for treating neurodegenerative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/652,435 Continuation US20040044022A1 (en) 1995-10-23 2003-08-28 Agent for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
US20020115682A1 true US20020115682A1 (en) 2002-08-22

Family

ID=20173218

Family Applications (6)

Application Number Title Priority Date Filing Date
US09/269,602 Expired - Lifetime US6187785B1 (en) 1995-10-23 1996-10-23 Agent for treating neurodegenerative disorders
US09/778,662 Abandoned US20010020028A1 (en) 1995-10-23 2001-02-06 Agents for treating neurodegenerative disorders
US10/057,688 Abandoned US20020115682A1 (en) 1995-10-23 2002-01-23 Agents for treating neurodegenerative disorders
US10/652,435 Abandoned US20040044022A1 (en) 1995-10-23 2003-08-28 Agent for treating neurodegenerative disorders
US11/004,001 Expired - Fee Related US7071206B2 (en) 1995-10-23 2004-12-02 Agents for treating neurodegenerative disorders
US11/361,628 Abandoned US20060140866A1 (en) 1995-10-23 2006-02-24 Agents for treating neurodegenerative disorders

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/269,602 Expired - Lifetime US6187785B1 (en) 1995-10-23 1996-10-23 Agent for treating neurodegenerative disorders
US09/778,662 Abandoned US20010020028A1 (en) 1995-10-23 2001-02-06 Agents for treating neurodegenerative disorders

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/652,435 Abandoned US20040044022A1 (en) 1995-10-23 2003-08-28 Agent for treating neurodegenerative disorders
US11/004,001 Expired - Fee Related US7071206B2 (en) 1995-10-23 2004-12-02 Agents for treating neurodegenerative disorders
US11/361,628 Abandoned US20060140866A1 (en) 1995-10-23 2006-02-24 Agents for treating neurodegenerative disorders

Country Status (11)

Country Link
US (6) US6187785B1 (en)
EP (1) EP0876818B1 (en)
AT (1) ATE229806T1 (en)
AU (1) AU7347496A (en)
CA (1) CA2269698C (en)
DE (1) DE69625518T2 (en)
DK (1) DK0876818T3 (en)
ES (1) ES2188793T3 (en)
HK (1) HK1016893A1 (en)
RU (1) RU2106864C1 (en)
WO (1) WO1997015225A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096342A1 (en) * 1995-10-23 2005-05-05 Medivation, Inc. Neurodegenerative disorders
US20070117834A1 (en) * 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
US20070179174A1 (en) * 2003-12-08 2007-08-02 Bachurin Sergei O Methods and compositions for slowing aging
US20080234310A1 (en) * 2003-12-08 2008-09-25 Bachurin Sergei O Methods and Compositions for Slowing Aging
US20100022580A1 (en) * 2008-01-25 2010-01-28 Hung David T New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole compounds and methods of use thereof
US20100056790A1 (en) * 2007-09-20 2010-03-04 D2E, Llc Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
US20100216814A1 (en) * 2008-10-31 2010-08-26 Hung David T Pyrido[4,3-b]indoles containing rigid moieties
US20110237582A1 (en) * 2009-09-23 2011-09-29 Rajendra Parasmal Jain Pyrido[3,4-b]indoles and methods of use
US8791132B2 (en) 2011-02-18 2014-07-29 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US8859561B2 (en) 2009-09-23 2014-10-14 Medivation Technologies, Inc. Pyrido[4,3-b]indoles and methods of use
US8999977B2 (en) 2008-03-24 2015-04-07 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
US9006234B2 (en) 2009-09-23 2015-04-14 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9035056B2 (en) 2011-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9199985B2 (en) 2011-02-18 2015-12-01 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US9260429B2 (en) 2008-03-24 2016-02-16 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
US9409910B2 (en) 2008-10-31 2016-08-09 Medivation Technologies, Inc. Azepino[4,5-B]indoles and methods of use
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363244C (en) * 2000-11-07 2006-06-13 Research In Motion Limited Multifunctional keyboard for a mobile communication device and method of operating the same
WO2004035580A1 (en) * 2002-10-21 2004-04-29 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
FR2885905A1 (en) * 2005-05-23 2006-11-24 Trophos Sa NOVEL CHEMICAL COMPOUNDS AND THEIR USES AS A MEDICINAL PRODUCT
WO2007032699A1 (en) * 2005-09-12 2007-03-22 Avdulov, Nikolai Andreevich (+)-and-(-)-trans-2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1h-pyrido[4,3-b] indole optical isomers
RU2338537C2 (en) * 2006-01-25 2008-11-20 Сергей Олегович Бачурин AGENT FOR TREATMENT OF SCHIZOPHRENIA ON BASIS OF HYDROGENATED PYDIDO (4,3-b) INDOLES (VERSIONS), PHARMACOLOGICAL AGENT ON ITS BASIS AND METHOD OF ITS APPLICATION
RU2317989C1 (en) 2006-08-24 2008-02-27 Андрей Александрович Иващенко SUBSTITUTED AZEPINO[4,3-b]INDOLES, PHARMACEUTICAL COMPOSITION, METHOD FOR THEIR PREPARING AND USING
US20100099700A1 (en) * 2006-09-20 2010-04-22 David Hung Hydrogenated pyrido (4,3-b) indoles for treating amyotrophic lateral sclerosis (als)
AU2007297618A1 (en) * 2006-09-20 2008-03-27 Medivation Neurology, Inc. Hydrogenated pyrido [4,3-b] indoles such as dimebon for treating canine Cognitive Dysfunction Syndrome
BRPI0718437A2 (en) * 2006-10-27 2013-11-19 Medivation Neurology Inc COMBINATION METHODS AND THERAPIES TO TREAT ALZHEIMER'S DISEASE USING DIMEBON AND DOLEPEZIL
RU2329044C1 (en) * 2006-11-16 2008-07-20 Андрей Александрович Иващенко Ligands of 5-ht6 receptors, pharmaceutical formulation, production method and medical product
RU2334514C1 (en) * 2006-12-01 2008-09-27 Институт физиологически активных веществ Российской Академии наук REMEDY FOR IMPROVEMENT OF COGNITIVE FUNCTIONS AND MEMORY BASED ON HYDRATED PYRIDO (4,3-b) INDOLES (VERSIONS), PHARMACOLOGICAL REMEDY BASED THEREON AND METHOD OF APPLICATION THEREOF
RU2340342C2 (en) * 2006-12-07 2008-12-10 Сергей Олегович Бачурин AGENT FOR TREATMENT OF ACUTE AND CHRONIC DISTURBANCES OF CEREBRAL CIRCULATION, INCLUDING STROKE ON BASIS OF HYDROGENATED PYRIDO (4,3-b)INDOLES (VERSIONS), PHARMACOLOGICAL AGENT ON ITS BASIS AND METHOD OF ITS APPLICATION
WO2008112238A1 (en) * 2007-03-12 2008-09-18 Grey Fox Llc 2, 8-dimethyl-5- [2- (6-methylpyridin-3-yl) -ethyl] -2,3,4, 5-tetrahydro- ih- pyrido [4, 3 -b] indole dihydrochloride (dimebon) for the treatment of chronic pain
RU2334747C1 (en) * 2007-04-05 2008-09-27 Андрей Александрович Иващенко SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-b]INDOLES, METHOD OF PRODUCTION AND APPLICATION THEREOF
RU2327480C1 (en) 2007-05-23 2008-06-27 Виктор Иванович Рощин Active ingredient of medicinal agent, medicinal agent, pharmaceutical conposition and method of dement syndrome treatment
RU2338533C1 (en) * 2007-06-28 2008-11-20 Сергей Олегович Бачурин AGENT POSSESSING ANXIOLYTHIC ACTION, ON BASIS OF HYDROGENATED PYRIDO (4,3-b) INDOLES (VERSIONS), PHARMACOLOGICAL AGENT ON ITS BASIS AND WAY OF ITS APPLICATION
TWI447117B (en) * 2007-10-25 2014-08-01 Medivation Technologies Inc New tetracyclic compounds
RU2007139634A (en) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) NEW THIAZOLE-, TRIAZOLE- OR OXADIAZOLE-CONTAINING TETRACYCLIC COMPOUNDS
JP2011507835A (en) * 2007-12-21 2011-03-10 アンドレイ・アレクサンドロビッチ・イワシェンコ Alpha-adrenergic receptor, dopamine, histamine, imidazoline and serotonin receptor ligands and uses thereof
US8715643B2 (en) * 2008-04-09 2014-05-06 Tokyo Metropolitan Institute Of Medical Science TDP-43-storing cell model
RU2374245C1 (en) * 2008-08-22 2009-11-27 Андрей Александрович Иващенко Ligand with wide range of simultaneous receptor activity, pharmaceutical composition, method of preparing said composition and medicinal agent
WO2010031054A1 (en) 2008-09-15 2010-03-18 Biovista, Inc. Compositions and methods for treating epilepsy
PA8843701A1 (en) 2008-09-29 2010-05-26 Abbott Lab INDOLINE DERIVATIVES AND METHODS TO USE THEM
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
US20100137215A1 (en) * 2008-11-25 2010-06-03 Concert Pharmaceuticals Inc. Novel tetrahydro-1h-pyrido[4,3-b]indoles
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8604074B2 (en) 2009-01-09 2013-12-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
SG173639A1 (en) * 2009-02-11 2011-09-29 Sunovion Pharmaceuticals Inc Histamine h3 inverse agonists and antagonists and methods of use thereof
EP2236160A3 (en) 2009-03-31 2011-12-14 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release dimebolin formulations
EP2236159A3 (en) 2009-03-31 2011-12-07 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release dimebolin compositions
TR200903014A1 (en) 2009-04-17 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Orally dispersed dimebolin compounds.
EP2424366B1 (en) 2009-04-29 2016-02-17 Medivation Technologies, Inc. Pyrido [4, 3-b]indoles and methods of use
WO2010127177A1 (en) 2009-04-29 2010-11-04 Medivation Technologies, Inc. Pyrido [4,3-b] indoles and methods of use
WO2011039675A2 (en) 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine transdermal therapeutic dosage forms
WO2011039670A1 (en) 2009-09-30 2011-04-07 Pfizer Inc. Novel forms of (2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b] indole)
WO2011039686A1 (en) 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
RU2428185C1 (en) * 2009-12-29 2011-09-10 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) PHARMACEUTICAL COMPOSITION FOR NEURODEGENERATIVE DISEASES OF HYDROGENATED PYRIDO(4,3-b)INDOLE, METHOD FOR PREPARING AND BASED DRUG
TR201001117A1 (en) 2010-02-15 2011-09-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Dimebolin and memantine combinations
EP2590647B1 (en) 2010-07-07 2017-11-08 Board of Regents of the University of Texas System Pro-neurogenic compounds
WO2012016708A1 (en) 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form comprising dimebolin and donepezil
WO2012016707A2 (en) 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form for the modified release of dimebolin
RU2451686C1 (en) * 2010-12-27 2012-05-27 Александр Васильевич Иващенко SUBSTITUTED HYDRATED TIENO-PYRROLO [3,2-c] PYRIDINES, LIGANDS, PHARMACEUTICAL COMPOSITION AND ITS APPLICATION METHOD
DE102012003065A1 (en) * 2012-02-13 2013-08-14 Friedrich-Schiller-Universität Jena New bivalent gamma-carboline derivatives, useful as anti-dementia drugs, cognition enhancers and/or substance for increasing memory capacity
WO2013130422A1 (en) 2012-02-27 2013-09-06 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
US20150315188A1 (en) * 2012-08-22 2015-11-05 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
EP2887803A4 (en) 2012-08-24 2016-08-03 Univ Texas Pro-neurogenic compounds
WO2014207241A1 (en) * 2013-06-28 2014-12-31 Alzprotect NEW Na-SUBSTITUTED CARBOLINE COMPOUNDS USABLE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
US9902713B2 (en) 2013-11-11 2018-02-27 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP2918792A1 (en) * 2014-03-13 2015-09-16 Siemens Aktiengesellschaft Steam power plant with spindle leakage steam conduit
CN109535157B (en) * 2018-12-03 2021-10-15 江苏科技大学 Paracetamol analog, and synthesis method and application thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1138164A1 (en) * 1963-04-25 1985-02-07 Shadurskij Konstantin S Antihistamine agent "dimebon"
DE1813229A1 (en) 1967-12-08 1970-08-20 Sumitomo Chemical Co gamma-carbolines and their salts and processes for their preparation
US3743740A (en) * 1968-10-31 1973-07-03 I Zhukova 3,6-dimethyl - 1,2,3,4,4a,9a - hexahydro-ypsilon-carboline dihydrochloride for treating mental diseases
GB1276113A (en) 1969-10-17 1972-06-01 Nii Farmakologii I Khim 3,6-DIMETHYL 1,2,3,4a,9a-HEXAHYDRO-gamma-CARBOLINE DIHYDROCHLORIDE
DE1952800C3 (en) 1969-10-20 1974-04-18 Nautschno-Issledowatelskij Institut Farmakologii I Chimioterapii, Moskau 3,6-dimethyl-1,2,3,4,4a, 9a-hexahydro-gamma-carboline dihydrochloride
US3718657A (en) * 1970-12-03 1973-02-27 Abbott Lab Certain-2-substituted-1,2,3,4-tetrahydro-beta or gamma carbolines
SE7414572L (en) * 1973-12-06 1975-06-09 Endo Lab
US4174453A (en) * 1973-12-06 1979-11-13 Endo Laboratories, Inc. Trans-hexahydro-pyrido-indoles
AR205452A1 (en) * 1973-12-06 1976-05-07 Endo Lab METHOD TO PREPARE NEW TRANS-2, 3, 4, 4A, 5, 9B-HEXAHYDRO-5-PHENYL-1H-PYRID (4,3-B) INDOLES
SE441448B (en) * 1977-05-23 1985-10-07 Pfizer SET TO MAKE HEXAHYDRO-GAMMA CARBOL COMPOUNDS
US4636563A (en) * 1985-09-16 1987-01-13 American Home Products Corporation Antipsychotic γ-carbolines
GB8600783D0 (en) 1986-01-14 1986-02-19 Merck Sharp & Dohme N-methyl-d-aspartate receptor antagonists
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US4985256A (en) * 1988-04-27 1991-01-15 Bionix Corporation Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
US6017957A (en) * 1989-08-08 2000-01-25 The United States Of America As Represented By The Department Of Health And Human Services Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents
EP0424179A3 (en) 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5319096A (en) * 1992-04-03 1994-06-07 Hoechst-Roussel Pharmaceuticals Inc. (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use
DE4212529A1 (en) * 1992-04-10 1993-10-14 Schering Ag Use of µ-carbolines as non-competitive glutamate antagonists
US5248690A (en) 1992-07-07 1993-09-28 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US6362160B1 (en) * 1993-06-30 2002-03-26 The Johns Hopkins University School Of Medicine Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseases
US5587384A (en) * 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
RU2140417C1 (en) 1995-10-17 1999-10-27 Институт физиологически активных веществ РАН Derivatives of hydrogenated pyrido[4,3-b]indoles, methods of their synthesis, pharmaceutical composition and method of patient treatment
RU2106864C1 (en) 1995-10-23 1998-03-20 Николай Серафимович Зефиров New approach to treatment of alzheimer's disease
US6391871B1 (en) * 1996-09-20 2002-05-21 John W. Olney Preventing neuronal degeneration in Alzheimer's disease
US5958919A (en) * 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US6379882B1 (en) * 1998-09-14 2002-04-30 Elan Pharmaceuticals, Inc. Method for selecting compounds for treating ischemia-related cellular damage
ES2415708T3 (en) * 1999-12-16 2013-07-26 Biogen Idec Ma Inc. Methods of treatment of ischemic or hemorrhagic lesion of the central nervous system through the use of anti-integrin alpha4 antagonists
RU2283108C2 (en) 2003-12-08 2006-09-10 Сергей Олегович Бачурин GEROPROTECTING AGENT BASED ON HYDROGENATED PYRIDO[4,3-b]INDOLES (VARIANTS), PHARMACOLOGICAL AGENT BASED ON THEREOF AND METHOD FOR ITS USING

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096342A1 (en) * 1995-10-23 2005-05-05 Medivation, Inc. Neurodegenerative disorders
US20060140866A1 (en) * 1995-10-23 2006-06-29 Zefirov Nikolai S Agents for treating neurodegenerative disorders
US7071206B2 (en) 1995-10-23 2006-07-04 Medivation, Inc. Agents for treating neurodegenerative disorders
US20070179174A1 (en) * 2003-12-08 2007-08-02 Bachurin Sergei O Methods and compositions for slowing aging
US20080234310A1 (en) * 2003-12-08 2008-09-25 Bachurin Sergei O Methods and Compositions for Slowing Aging
US20070117834A1 (en) * 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
US20070117835A1 (en) * 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
US7935823B2 (en) 2007-09-20 2011-05-03 D2E, Llc Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
US20100056790A1 (en) * 2007-09-20 2010-03-04 D2E, Llc Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
US9115137B2 (en) 2008-01-25 2015-08-25 Medivation Technologies, Inc. 2,3,4,5-tetrahydro-1H-pyrido[4,3-B]indole compounds and methods of use thereof
US20100022580A1 (en) * 2008-01-25 2010-01-28 Hung David T New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole compounds and methods of use thereof
US9260429B2 (en) 2008-03-24 2016-02-16 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
US8999977B2 (en) 2008-03-24 2015-04-07 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
US9469641B2 (en) 2008-03-24 2016-10-18 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
US9051314B2 (en) 2008-03-24 2015-06-09 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
US9034869B2 (en) 2008-03-24 2015-05-19 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
US9458155B2 (en) 2008-10-31 2016-10-04 Medivation Technologies, Inc Pyrido[4,3-b]indoles containing rigid moieties
US9481676B2 (en) 2008-10-31 2016-11-01 Medivation Technologies, Inc. Azepino[4,5-B]indoles and methods of use
US20100216814A1 (en) * 2008-10-31 2010-08-26 Hung David T Pyrido[4,3-b]indoles containing rigid moieties
US8907097B2 (en) 2008-10-31 2014-12-09 Medivation Technologies, Inc. Pyrido[4,3-b]indoles containing rigid moieties
US8906925B2 (en) 2008-10-31 2014-12-09 Medivation Technologies, Inc. Pyrido[4,3-B]indoles containing rigid moieties
US9409910B2 (en) 2008-10-31 2016-08-09 Medivation Technologies, Inc. Azepino[4,5-B]indoles and methods of use
US9006234B2 (en) 2009-09-23 2015-04-14 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
US9199996B2 (en) 2009-09-23 2015-12-01 Medivation Technologies, Inc. Pyrido[4,3-B]indoles and methods of use
US9045482B2 (en) 2009-09-23 2015-06-02 Medivation Technologies, Inc. Pyrido[4,3-B]indoles and methods of use
US9271971B2 (en) 2009-09-23 2016-03-01 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
US9079904B2 (en) 2009-09-23 2015-07-14 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
US9085580B2 (en) 2009-09-23 2015-07-21 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
US8859561B2 (en) 2009-09-23 2014-10-14 Medivation Technologies, Inc. Pyrido[4,3-b]indoles and methods of use
US20110237582A1 (en) * 2009-09-23 2011-09-29 Rajendra Parasmal Jain Pyrido[3,4-b]indoles and methods of use
US9580425B2 (en) 2009-09-23 2017-02-28 Medivation Technologies, Inc. Pyrido[3,4-b] indoles and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9433626B2 (en) 2010-02-18 2016-09-06 Medivation Technologies, Inc. Pyrido[4,3-B]indole and pyrido[3,4-B]indole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
US9035056B2 (en) 2011-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9211287B2 (en) 2011-02-18 2015-12-15 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
US9199985B2 (en) 2011-02-18 2015-12-01 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US9006263B2 (en) 2011-02-18 2015-04-14 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US8815843B2 (en) 2011-02-18 2014-08-26 Medivation Technologies, Inc. Compounds and methods of treating diabetes
US9527854B2 (en) 2011-02-18 2016-12-27 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US9550782B2 (en) 2011-02-18 2017-01-24 Medivation Technologies, Inc. Compounds and methods for treating diabetes
US8791132B2 (en) 2011-02-18 2014-07-29 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension

Also Published As

Publication number Publication date
ES2188793T3 (en) 2003-07-01
DE69625518T2 (en) 2003-09-04
CA2269698C (en) 2007-09-18
RU2106864C1 (en) 1998-03-20
WO1997015225A1 (en) 1997-05-01
EP0876818A2 (en) 1998-11-11
US20040044022A1 (en) 2004-03-04
HK1016893A1 (en) 1999-11-12
US20050096342A1 (en) 2005-05-05
ATE229806T1 (en) 2003-01-15
US20060140866A1 (en) 2006-06-29
US20010020028A1 (en) 2001-09-06
US7071206B2 (en) 2006-07-04
DE69625518D1 (en) 2003-01-30
DK0876818T3 (en) 2003-03-31
US6187785B1 (en) 2001-02-13
AU7347496A (en) 1997-05-15
EP0876818B1 (en) 2002-12-18
EP0876818A4 (en) 1999-01-07
CA2269698A1 (en) 1997-05-01

Similar Documents

Publication Publication Date Title
US6187785B1 (en) Agent for treating neurodegenerative disorders
US11426419B2 (en) Compositions and methods for the repair of myelin
CN101987849B (en) Method of treatment of age-related macular degeneration(AMD)
JP2010507672A (en) Methods and combination therapies for treating Alzheimer&#39;s disease
JP2010511616A (en) Means for improving cognitive function and memory based on hydrogenated pyrido (4,3-b) indoles (isomers), pharmacological means based on the means, and methods for use of the means
EA015256B1 (en) Tetrahydroisoquinoline derivatives to enhance memory function
US5693645A (en) Use of spiperone or spiperone derivatives as immunosuppressant agents
CN110167562A (en) DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC are directed to the protective effect for causing the drug of ion channel disease
CN104884053B (en) For improving the intelligence development composition of memory performance
JP2021507945A (en) Compositions and treatments for neuropathy, including dementia
US20230129151A1 (en) Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
RU2451512C2 (en) Neurogenesis mediated with 4-acylaminopyridine derivatives
JPH0354922B2 (en)
US5484788A (en) Buspirone as a systemic immunosuppressant
US20030191152A1 (en) Use of halogenated heterocyclic compounds in the treatment of sexual dysfunction and cardiovascular disease
JPH0813741B2 (en) Anti-dementia agent
JPH1179995A (en) Therapeutic agent for multiple sclerosis
JP6105111B1 (en) Composition for improving autism spectrum disorder
US20110224300A1 (en) USE OF POTASSIUM 2-(a- HYDROXYPENTYL) BENZOATE IN THE MANUFACTURE OF MEDICAMENTS FOR PREVENTING AND/OR TREATING SENILE DEMENTIA
TW202120083A (en) Composition including clavulanic acid and valproic acid, and use thereof
JP2003221337A (en) Dementia treating agent containing acetamide derivative as active component
JPH0541603B2 (en)
JPH06505255A (en) Use of tetrahydro-thienopyridindole derivatives in the preparation of drugs for the treatment of dermatological diseases
KR20050031692A (en) Composition comprising mefenamic acid as an effective component for prevention and treatment of dementia, and learning and memory impairment

Legal Events

Date Code Title Description
AS Assignment

Owner name: SELENA PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZEFIROV, NIKOLAI S.;AFANASIEV, ANDREI Z.;AFANASIEVA, SVETLANA V.;AND OTHERS;REEL/FRAME:012560/0470;SIGNING DATES FROM 19981112 TO 19981124

AS Assignment

Owner name: MEDIVATION, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SELENA PHARMACEUTICALS, INC.;REEL/FRAME:014237/0173

Effective date: 20031216

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: MEDIVATION NEUROLOGY, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDIVATION, INC.;REEL/FRAME:021445/0040

Effective date: 20080328

AS Assignment

Owner name: AFANAS'EV, A. Z., RUSSIAN FEDERATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUTE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES OF THE RUSSIAN ACADEMY OF SCIENCES;REEL/FRAME:021452/0368

Effective date: 19970123

Owner name: AFANAS'EVA, S. V., RUSSIAN FEDERATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUTE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES OF THE RUSSIAN ACADEMY OF SCIENCES;REEL/FRAME:021452/0368

Effective date: 19970123

Owner name: GRIGOR'EV, V. V., RUSSIAN FEDERATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUTE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES OF THE RUSSIAN ACADEMY OF SCIENCES;REEL/FRAME:021452/0368

Effective date: 19970123

Owner name: GRIGOR'EVA, I. V., RUSSIAN FEDERATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUTE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES OF THE RUSSIAN ACADEMY OF SCIENCES;REEL/FRAME:021452/0368

Effective date: 19970123

Owner name: TKACHENKO, S. E., RUSSIAN FEDERATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUTE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES OF THE RUSSIAN ACADEMY OF SCIENCES;REEL/FRAME:021452/0368

Effective date: 19970123

Owner name: ZEFIROV, N. S., RUSSIAN FEDERATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUTE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES OF THE RUSSIAN ACADEMY OF SCIENCES;REEL/FRAME:021452/0368

Effective date: 19970123

Owner name: BACHURIN, S. O., RUSSIAN FEDERATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUTE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES OF THE RUSSIAN ACADEMY OF SCIENCES;REEL/FRAME:021452/0368

Effective date: 19970123

Owner name: YUROVSKAYA, M. A., RUSSIAN FEDERATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUTE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES OF THE RUSSIAN ACADEMY OF SCIENCES;REEL/FRAME:021452/0368

Effective date: 19970123

Owner name: CHETVERIKOV, V. P., RUSSIAN FEDERATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUTE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES OF THE RUSSIAN ACADEMY OF SCIENCES;REEL/FRAME:021452/0368

Effective date: 19970123

Owner name: BUKATINA, E. E., RUSSIAN FEDERATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUTE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES OF THE RUSSIAN ACADEMY OF SCIENCES;REEL/FRAME:021452/0368

Effective date: 19970123